Organisation paid for research Program year 2025 Source: CMS Open Payments

Antelope Valley Clinical Trials

Neither a doctor nor a teaching hospital

Research payments

$482,435

286 payments

Through program year 2025, Antelope Valley Clinical Trials is reported as receiving $482,435 in research payments, across 286 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $47,506 4
2024 Research $59,139 119
2023 Research $48,159 67
2022 Research $118,043 23
2021 Research $205,628 68
2020 Research $3,960 5

Breakdown

Who paid Research payments · program years 2020–2025
  1. Teva Pharmaceuticals USA, Inc. $189,711 69 payments
  2. Pfizer Inc. $112,085 29 payments
  3. Amgen Inc. $81,558 8 payments
  4. Novartis Pharmaceuticals Corporation $69,028 8 payments
  5. Dermavant Sciences, Inc. $28,800 171 payments
  6. ALK-Abello, Inc $1,253 1 payment
Studies the money was for Research payments · program years 2020–2025
  1. Abrocitinib Expanded Access Protocol for the Treatment of Adolescents and Adults With Moderate to Severe Atopic Dermatitis $98,656 28 payments
  2. CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma $88,107 48 payments
  3. A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma $64,882 8 payments
  4. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Remibrutinib (Lou064) to Investigate the Efficacy, Safety and Tolerability for 52 Weeks in Adult Chronic Spontaneous Urticaria (Csu) Patients Inadequately Controlled By H1-Antihi $57,205 1 payment
  5. CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma $36,722 13 payments
  6. A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma $30,938 1 payment
  7. SHUTTLE P3 AD Adult Combo TCS $15,249 2 payments
  8. STARLIGHT P2 LCM Asthma $15,142 2 payments
  9. A Phase 2B Randomized Doubleblind 12Week Placebocontrolled Study With A 12Week Doubleblind Extension Period to Evaluate the Efficacy Safety and Tolerability of Ritlecitinib Pf06651600 in Adult Participants With Chronic Spontaneous Urticaria $13,429 1 payment
  10. P3 AD Adult Combo TCS $12,991 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record